Abstract
Background and Aim: Polycystic Ovary Syndrome (PCOS) affects 5–16% of women of reproductive age and is associated with significant reproductive, metabolic, and psychological consequences. Lifestyle modification, including diet and physical activity, is universally recommended as first-line therapy. However, most clinical studies and guidelines treat PCOS as a homogeneous condition, overlooking the heterogeneity defined by the Rotterdam phenotypes. This reduces the applicability of current recommendations. The novelty of this review lies in focusing on phenotype-specific responses to lifestyle interventions. The aim is to summarize available evidence on dietary approaches, physical activity, supplementation, and behavioral factors across PCOS phenotypes and to identify gaps for future research. Methods: A narrative review was performed using PubMed, Google Scholar, and ResearchGate. Eligible publications included randomized controlled trials, systematic reviews, meta-analyses, and international guidelines published after 2018. Search terms combined PCOS, phenotype, diet, physical activity, insulin resistance, hyperandrogenism, supplementation, smoking, and sleep. Results: Evidence indicates that aerobic exercise, high-intensity interval training, low-AGE and high-fiber hypocaloric diets, and selected supplements such as β-hydroxybutyrate and N-acetylcysteine improve metabolic and hormonal outcomes. These effects are most pronounced in classical phenotypes A and B, characterized by hyperandrogenism and insulin resistance. Non-hyperandrogenic phenotypes, such as D, show limited response to interventions targeting androgen excess. Behavioral factors, including smoking and sleep disturbances, aggravate metabolic dysfunctions and worsen outcomes in hyperandrogenic phenotypes. Conclusions: Lifestyle modification remains central to PCOS management, but its effectiveness is not uniform across phenotypes. Tailoring dietary, exercise, and adjunctive strategies to the endocrine and metabolic characteristics of each phenotype may improve outcomes. Future research should prioritize phenotype-stratified trials to provide evidence-based recommendations that reflect the heterogeneity of PCOS.